Table 4 presents the most common Grade 3 or 4 laboratory abnormalities based on laboratory data, occurring in at least 10% of patients.
Other clinically important Grade 3 or 4 laboratory abnormalities (based on laboratory data) that occurred in less than 10% of patients treated with CARVYKTI include gamma glutamyl transferase increased, fibrinogen decreased, aspartate aminotransferase increased, hypokalemia, alanine aminotransferase increased, hyponatremia, alkaline phosphatase increased, hypertriglyceridemia, hypomagnesemia, hypoalbuminemia, hypocalcemia, and blood bilirubin increased.
The safety data described in this section reflect the exposure of 97 adult patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 study (USA cohort) to CARVYKTI and includes 17 patients (18%) with manufacturing failures either because they received CARVYKTI that did not meet product release specifications or there were insufficient data to confirm product release specifications for CARVYKTI. Patients received CARVYKTI across a dose range of 0.51 to 0.95×10
6CAR-positive viable T cells/kg body weight
[see
Clinical Studies (14)]
. Patients with a history of CNS disease (such as seizure or cerebrovascular ischemia) or requiring ongoing treatment with chronic immunosuppression were excluded. The median duration of follow-up was 18 months. The median age of the study population was 61 years (range: 43 to 78 years); 36% were 65 years or older, and 59% were men. The Eastern Cooperative Oncology Group (ECOG) performance status at baseline was 0 in 40%, 1 in 56%, and 2 in 4% of patients. Three of the patients treated with CARVYKTI had a creatinine clearance of <45 mL/min at baseline. For the details about the study population, see
Clinical Studies (14).
The most common (greater or equal to 10%) Grade 3 or higher nonlaboratory adverse reactions were infections-pathogen unspecified (19%), pneumonia (13%), hematologic malignancy (10%) and hypotension (10%).
The most common nonlaboratory adverse reactions (incidence greater than or equal to 20%) included pyrexia, CRS, hypogammaglobulinemia, hypotension, musculoskeletal pain, fatigue, infections of unspecified pathogen, cough, chills, diarrhea, nausea, encephalopathy, decreased appetite, upper respiratory tract infection, headache, tachycardia, dizziness, dyspnea, edema, viral infections, coagulopathy, constipation, and vomiting.
Serious adverse reactions occurred in 55% of patients. The most common non-laboratory (greater than or equal to 5%) serious adverse reactions included CRS (21%), sepsis (7%), encephalopathy (10%), and pneumonia (8%). Fatal adverse reactions occurred in 9% of patients.
Table 5 summarizes the adverse reactions that occurred in at least 10% of patients treated with CARVYKTI.
Other clinically important adverse reactions that occurred in less than 10% of patients treated with CARVYKTI include the following:
- Cardiac disorders: cardiac arrhythmias
Represents multiple related terms
(8%), chest pain
(7%)
- Eye disorders: diplopia (1%)
- Gastrointestinal disorders: dysphagia (1%)
- Immune system disorders:HLH (1%), hypersensitivity reaction (5%)
- Infections and Infestations:bacterial infections
(9%), urinary tract infection
(4.1%)
- Injury, Poisoning and Procedural complications: fall (3.1%)
- Metabolism and Nutrition Disorders: tumor lysis syndrome (1%)
- Musculoskeletal and Connective tissue disorders: posture abnormal (1%)
- Nervous system disorders: aphasia
(8%), ataxia
(8%), peripheral neuropathy
(7%), tremor (6%), parkinsonism (4.1%), micrographia (4.1%), dysgraphia (3.1%), reduced facial expression (3.1%), cranial nerve palsies (3.1%), bradykinesia (2.1%), paresis
(1%), cogwheel rigidity (1%), cerebrovascular accident (1%), seizure (1%), slow speech (1%), nystagmus (1%)
- Psychiatric disorders: delirium
(5%), depression
(4.1%), psychomotor retardation (1%)
- Renal and urinary disorders: renal failure
(7%)
- Skin and subcutaneous tissues: rash
(8%)
- Vascular Disorders: thrombosis
(5%)
Laboratory Abnormalities
Table 6 presents the most common Grade 3 or 4 laboratory abnormalities based on laboratory data, occurring in at least 10% of patients.
Table 6: Grade 3 or 4 laboratory abnormalities in at least 10% of patients treated with CARVYKTI in CARTITUDE-1 (N=97)| Laboratory Abnormality | Grade 3 or 4 (%) |
|---|
| Laboratory abnormalities graded using NCI Common Terminology Criteria for Adverse Events version 5.0. Laboratory abnormalities are sorted by decreasing frequency in the Grade column. |
| Lymphopenia | 99 |
| Neutropenia | 98 |
| White blood cell decreased | 98 |
| Anemia | 72 |
| Thrombocytopenia | 63 |
| Aspartate aminotransferase increased | 21 |
Other clinically important Grade 3 or 4 laboratory abnormalities (based on laboratory data) that occurred in less than 10% of patients treated with CARVYKTI include the following: fibrinogen decreased, hypoalbuminemia, alanine aminotransferase increased, hyponatremia, hypocalcemia, gamma glutamyl transferase increased, alkaline phosphatase increased, hypokalemia, blood bilirubin increased.
Risk Summary
There are no available data on the use of CARVYKTI in pregnant women. No reproductive and developmental toxicity studies in animals have been conducted with CARVYKTI to assess whether it can cause fetal harm when administered to a pregnant woman. It is not known whether CARVYKTI has the potential to be transferred to the fetus and cause fetal toxicity. Based on the mechanism of action, if the transduced cells cross the placenta, they may cause fetal toxicity, including B-cell lymphocytopenia and hypogammaglobulinemia. Therefore, CARVYKTI is not recommended for women who are pregnant, or for women of childbearing potential not using contraception. Pregnant women should be advised that there may be risks to the fetus. Pregnancy after CARVYKTI therapy should be discussed with the treating physician.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively.
Risk Summary
There is no information regarding the presence of CARVYKTI in human milk, the effect on the breastfed infant, and the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for CARVYKTI and any potential adverse effects on the breastfed infant from CARVYKTI or from the underlying maternal condition.
Pregnancy Testing
Pregnancy status for females of child-bearing age should be verified prior to starting treatment with CARVYKTI.
Contraception
There are insufficient data to provide a recommendation concerning duration of contraception following treatment with CARVYKTI.
In clinical trials, female patients of childbearing potential were advised to practice a highly effective method of contraception and male patients with partners of childbearing potential or whose partners were pregnant were instructed to use a barrier method of contraception, until one year after the patient has received CARVYKTI infusion.
See the prescribing information for lymphodepleting chemotherapy for information on the need for contraception in patients who receive the lymphodepleting chemotherapy.
Infertility
There are no data on the effect of CARVYKTI on fertility.
Specific Populations
The pharmacokinetics of CARVYKTI (C
maxand AUC
0–28d) were not impacted by age (27 to 78 years), gender, body weight, race, mild hepatic dysfunction [(total bilirubin ≤ upper limit of normal (ULN) and aspartate aminotransferase > ULN) or (ULN < total bilirubin ≤1.5 times ULN)], mild renal dysfunction (60 mL/min ≤ creatinine clearance [CRCL] <90 mL/min) or moderate renal dysfunction (30 mL/min ≤ creatinine clearance <60 mL/min). Formal renal and hepatic impairment studies of CARVYKTI were not conducted.
CARTITUDE-4
Efficacy of CARVYKTI was evaluated in CARTITUDE-4, a randomized, open-label, multicenter controlled study in adult patients with relapsed and lenalidomide-refractory multiple myeloma, who previously received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. A total of 419 patients were randomized 1:1 to receive either a sequence of apheresis, bridging therapy, lymphodepletion and CARVYKTI (n=208) or standard therapy which included daratumumab, pomalidomide and dexamethasone (DPd) or bortezomib, pomalidomide and dexamethasone (PVd) selected by physician prior to randomization based on patient's prior antimyeloma therapy (n=211). Randomization was stratified by physician's choice of treatment (DPd vs. PVd), ISS (I vs. II vs. III) and number of prior lines of therapy (1 vs. 2 or 3).
Patients with known active or prior history of central nervous system involvement, patients who exhibit clinical signs of meningeal involvement of multiple myeloma and patients with a history of Parkinson's disease or other neurodegenerative disorder, were excluded from the trial.
In the overall study population (N=419), the median age was 61 years (range: 27 to 80 years), 57% were male, 75% were White, 3% were Black or African American, 9% were Asian, and 7% were Hispanic or Latino. Most patients (94%) were International Staging System (ISS) Stage I or II. High-risk cytogenetics [presence of t(4:14), (14:16), and 17p13 del] were present in 34% of patients. Nineteen percent of patients had presence of soft tissue plasmacytoma.
Patients had received a median of 2 (range: 1 to 3) prior lines of therapy and 85% of patients had received prior autologous stem cell transplantation (ASCT). Ninety-nine percent of patients were refractory to their last line of prior therapy. Forty-seven percent were refractory to a proteasome inhibitor (PI) and 100% were refractory to an immunomodulatory agent.
All 208 patients randomized to the CARVYKTI arm underwent apheresis, twelve (6%) were not treated with CARVYKTI due to progressive disease (n=10) or death (n=2), and twenty (10%) progressed prior to infusion with CARVYKTI but were able to receive CARVYKTI as subsequent therapy. Eight (4%) patients received CAR-T positive T cells that did not meet product release specification for CARVYKTI (non-conforming product).
Patients randomized to CARVYKTI were to receive lymphodepleting chemotherapy consisting of fludarabine 30 mg/m
2/day and cyclophosphamide 300 mg/m
2/day concurrently for 3 days followed by CARVYKTI infusion 5 to 7 days after start of lymphodepleting chemotherapy. At least one cycle of DPd or PVd bridging therapy was received for disease control between leukapheresis and the start of the lymphodepleting chemotherapy.
CARVYKTI was administered as a single IV infusion 5 to 7 days after the start of a lymphodepleting chemotherapy at a median dose of 0.71×10
6CAR-positive viable T-cells/kg (range: 0.39 to 1.07×10
6cells/kg).
In the 176 patients that received CARVYKTI as study treatment, the median time from the day after receipt of apheresis material at manufacturing facility to release of product for infusion was 44 days (range: 25 to 127 days) and the median time from first apheresis to CARVYKTI infusion was 79 days (range: 45 days to 246 days).
The primary efficacy measure was progression-free survival (PFS) analyzed based on the Intent-To-Treat Analysis Set.
The efficacy results for CARTITUDE-4 study are summarized in Table 8, Figure 1 and Figure 2 below.
Table 8: Efficacy results for CARTITUDE-4 | CARVYKTI
(N=208)
| Standard Therapy
(N=211)
|
|---|
NE=not estimable; CI=confidence interval
All efficacy endpoints are analyzed based on the Intent to treat analysis set
|
| Primary Efficacy Analysis (median duration of follow up of 15.9 months) | - | - |
| Progression-Free Survival Per the International Myeloma Working Group (IMWG) consensus, as assessed by IRC | - | - |
| Number of events, n (%) | 65 (31.3) | 119 (56.4) |
| Median, months [95% CI]
Kaplan-Meier estimate | NE [22.8, NE] | 12 [9.8, 14.0] |
| Hazard ratio [95% CI]
Based on a stratified Cox proportional hazards model. A hazard ratio <1 indicates an advantage for CARVYKTI Arm. For all stratified analyses, stratification was based on investigator's choice (PVd or DPd), ISS staging (I, II, III) and number of prior lines (1 vs. 2 or 3) as randomized. | 0.41 [0.30, 0.56] | - |
| p-value
Stratified log-rank test | <0.0001 | - |
| Complete Response or Better Rate
, % [95% CI]
| 74.0 [67.5, 79.9] | 22.3 [16.8, 28.5] |
| p-value
Stratified Cochran-Mantel-Haenszel Chi-Squared test | <0.0001 | - |
| Stringent Complete Response
(sCR), n (%)
| 137 (65.9) | 38 (18.0) |
| Complete Response
(CR), n (%)
| 17 (8.2) | 9 (4.3) |
| Overall Response Rate, ORR (sCR + CR + VGPR + PR), % [95% CI] | 84.6 [79.0, 89.2] | 67.8 [61.0, 74.0] |
| p-value
| <0.0001 | - |
| Very Good Partial Response
(VGPR), n (%)
| 16 (7.7) | 49 (23.2) |
| Partial Response
(PR), n (%)
| 6 (2.9) | 47 (22.3) |
| Second Interim Analysis (median duration of follow up of 33.6 months) | - | - |
| Overall Survival (OS) | - | - |
| Number of events (%) | 50 (24.0%) | 83 (39.3%) |
| Number of censored (%) | 158 (76.0%) | 128 (60.7%) |
| Kaplan-Meier estimate (months) | - | - |
| Median (95% CI)
| NE (NE, NE) | NE (37.75, NE) |
| p-value
| 0.001 | - |
| Hazard ratio (95% CI)
| 0.55 (0.39, 0.79) | - |
The estimated PFS rate at 12 months was 75.9% (95% CI: 69.4%, 81.1%) in the CARVYKTI arm and 49.5% (95% CI: 42.3%, 56.3%) in the standard therapy arm.
In the CARVYKTI arm, the estimated median duration of response (DOR) has not been reached in patients who achieved PR or better or in patients who achieved CR or better. In the standard therapy arm, the estimated median DOR was 16.6 months (95% CI: 12.9, NE).
| Figure 1. Kaplan-Meier Curve of PFS in CARTITUDE-4 (Intent-To-Treat Analysis Set) |
|---|
Note: Intent-to-treat analysis set consists of subjects who were randomized in the study.
Data cutoff date: November 1, 2022
|
|
At the time of primary PFS analysis, the interim analysis of overall survival (OS) did not meet criteria for statistical significance. With an estimated median follow-up of 33.6 months, a prespecified second interim analysis showed a statistically significant improvement in OS in the CARVYKTI arm compared to the standard therapy arm.
A higher proportion of patients in the CARVYKTI arm compared to the standard therapy arm died within the first 10 months of randomization as shown in Figure 2.
| Figure 2: Kaplan-Meier Plot of Overall Survival (Intent-to-Treat Analysis) at Second Interim Analysis |
|---|
| Data cutoff date: 01 May 2024. |
|
CARTITUDE-1
The efficacy of CARVYKTI was evaluated in CARTITUDE-1, an open-label, single-arm, multicenter trial in adult patients with relapsed or refractory multiple myeloma, who previously received at least 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
[see
Adverse Reactions (6.1)]
.
Patients with known active or prior history of significant central nervous system (CNS) disease, including CNS multiple myeloma, plasma cell leukemia, allogeneic stem cell transplant within 6 months before apheresis or ongoing treatment with immunosuppressants, creatinine clearance <40 mL/min, absolute lymphocyte concentration <300/µL, absolute neutrophil count <750 cells/mm
3, platelet count <50,000/mm
3, hepatic transaminases >3 times the upper limit of normal, cardiac ejection fraction <45%, or with active serious infection were excluded from the trial.
Of the 113 patients who underwent leukapheresis, 16 patients did not receive CARVYKTI due to progressive disease (n=2), death (n=9), or withdrawal from study (n=5). There were 97 patients in the efficacy evaluable population who received CARVYKTI, including 17 patients (18%) with manufacturing failures either because they received CARVYKTI that did not meet product release specifications for CARVYKTI or received CARVYKTI for which there were insufficient data to confirm product release specifications for CARVYKTI.
Of the 97 efficacy-evaluable patients, the median age was 61 years (range: 43 to 78 years), 59% were male, 71% were white, and 18% were black. Most patients (86%) were ISS Stage I or II. Of the 91 patients for whom baseline cytogenetic data were available, high-risk cytogenetics (presence of t(4:14), t(14:16), or 17p13 del) were present in 24% of patients. Thirteen percent of the patients had extramedullary disease.
The median number of prior lines of therapy was 6 (range: 3 to 18), with 82% of patients receiving 4 or more prior lines of therapy, 90% of patients had received prior autologous stem cell transplantation (ASCT) and 8% of patients received an allogeneic transplant. Ninety-nine percent of patients were refractory to their last line of prior therapy, and 88% were refractory to a proteasome inhibitor (PI), immunomodulatory agent, and anti-CD38 antibody.
Most patients (75%) treated with CARVYKTI received bridging therapy for control of their multiple myeloma during the manufacturing process. The median time from leukapheresis to product availability was 32 days (range: 27 to 66 days).
The most commonly used agents as bridging therapies (≥20% of patients) included dexamethasone: 62 patients (64%), bortezomib: 26 patients (27%), cyclophosphamide: 22 patients (23%), and pomalidomide: 21 patients (22%).
The efficacy results for CARTITUDE-1 Study are summarized in Table 9 below.
The major efficacy outcome measures were overall response rate, complete response rate and duration of response as assessed by the Independent Review Committee (IRC) using International Myeloma Working Group (IMWG) criteria (see
Table 9). The median time to first response was 1 month (range: 0.9 to 10.7 months).
Table 9: Summary of efficacy results for CARTITUDE-1 based on IRC using IMWG criteria and duration of response results | CARVYKTI treated
(N=97)
|
|---|
| Notes: Based on a median duration of follow-up of 28 months. |
| CI=confidence interval; IRC=Independent Review Committee; IMWG=International Myeloma Working Group; NE=not estimable. |
| Overall Response Rate (sCR
All complete responses were stringent CRs. + VGPR + PR) n (%)
| 95 (97.9) |
| 95% CI (%) | (92.7, 99.7) |
| Stringent complete response (sCR)
n (%)
| 78 (80.4) |
| 95% CI
Exact 95% confidence interval. (%)
| (71.1, 87.8) |
| Very good partial response (VGPR) n (%) | 14 (14.4) |
| 95% CI
(%)
| (8.1, 23.0) |
| Partial response (PR) n (%) | 3 (3.1) |
| 95% CI
(%)
| (0.6, 8.8) |
| Duration of Response (DOR)
The estimated DOR rate was 60.3% (95% CI: 49.6%, 69.5%) at 24 months and 51.2% (95% CI: 39.0%, 62.1%) at 30 months. | - |
Number of responders
DOR (Months):Median (95% CI)
Kaplan-Meier estimate. | 95
NE (23.3, NE)
|
Number of responders with sCR
DOR if best response is sCR
(Months):Median (95% CI)
| 78
NE (28.3, NE)
|
Number of responders with VGPR or better
DOR if best response is VGPR or better (Months):Median (95% CI)
| 92
NE (24.4, NE)
|
The IRC assessed overall response in the 113 patients that underwent leukapheresis was 84% (95% CI: 76, 90) with stringent CR rate of 69% (95% CI: 60, 77), VGPR rate of 12% (95% CI: 7, 20) and PR rate of 3% (95% CI: 1, 8).
Increased Early Mortality
Inform patients of the risk of early mortality. In a clinical study, treatment in the CARVYKTI arm was associated with a higher rate of death (14%) compared to the control arm (12%) in the first 10 months from randomization. This higher rate of death was observed before receiving CARVYKTI and after treatment with CARVYKTI. The reasons for death were progression of multiple myeloma and adverse events
[see
Warnings and Precautions (5.1),
Clinical Studies (14)]
.
Cytokine Release Syndrome (CRS)
Signs or symptoms of CRS, including fever, chills, fatigue, headache, tachycardia, hypotension, hypoxia, dizziness/lightheadedness or organ toxicities
[see
Warnings and Precautions (5.2),
Adverse Reactions (6.1)].
Neurologic Toxicities
Signs or symptoms associated with neurologic events, some of which occur days, weeks or months following the infusion including
[see
Warnings and Precautions (5.3),
Adverse Reactions (6.1)]
:
ICANS:e.g., aphasia, encephalopathy, depressed level of consciousness, seizures, delirium, dysgraphia
Parkinsonism:e.g., tremor, micrographia, bradykinesia, rigidity, shuffling gait, stooped posture, masked facies, apathy, flat affect, lethargy, somnolence
Guillain Barré Syndrome:e.g., motor weakness and polyradiculoneuritis
Peripheral Neuropathy:e.g., peripheral motor and/or sensory nerve dysfunction
Cranial Nerve Palsies:e.g., facial paralysis, facial numbness
Prolonged and Recurrent Cytopenias
Signs or symptoms associated with bone marrow suppression including neutropenia, thrombocytopenia, anemia, or febrile neutropenia for several weeks or months. Signs or symptoms associated with bone marrow suppression may recur
[see
Warnings and Precautions (5.5),
Adverse Reactions (6.1)]
.
Infections
Signs or symptoms associated with infection
[see
Warnings and Precautions (5.6),
Adverse Reactions (6.1)]
.
Hypersensitivity Reactions
Signs or symptoms associated with hypersensitivity reactions including flushing, chest tightness, tachycardia, and difficulty breathing
[see
Warnings and Precautions (5.8)].
Immune Effector Cell-associated Enterocolitis
Signs or symptoms including persistent and severe diarrhea, abdominal pain and weight loss, post-infusion. Signs or symptoms of gastrointestinal perforation
[see
Warnings and Precautions (5.9)].
Secondary Malignancies
Secondary hematological malignancies, including myelodysplastic syndrome, acute myeloid leukemia, and T-cell malignancies (including in GI tract) have occurred
[see
Boxed Warning,
Warnings and Precautions (5.10),
Adverse Reactions (6.1,
6.2)].
Advise patients of the need to:
- Have periodic monitoring of blood counts before and after CARVYKTI infusion
[see
Warnings and Precautions (5.5)]
.
- Contact Janssen Biotech, Inc. at 1-800-526-7736 if they are diagnosed with a secondary malignancy
[see
Warnings and Precautions (5.10)]
.
- Avoid driving for at least 2 weeks
[see
Warnings and Precautions (5.3)]
.
- Tell their physician about their treatment with CARVYKTI before receiving a live virus vaccine
[see
Warnings and Precautions (5.7)]
.
Manufactured/Marketed by:
Janssen Biotech, Inc.
Horsham, PA 19044, USA
U.S. License Number 1864
Marketed by:
Legend Biotech
Somerset, NJ 08873, USA
For patent information: www.janssenpatents.com
© Johnson & Johnson and its affiliates 2022–2025